Author:
P.R. KAMCHATNOV1, R.A. CHEREMIN2, L.A. SKIPETROVA2, A.V. CHUGUNOV1
1Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Medical University” of the Ministry of Health of the Russian Federation, Moscow
2State Budgetary Healthcare Institution “Center for Speech Pathology and Neurorehabilitation of the Moscow Department of Health”
Place of publication:
THERAPY No. 9 (61) 2022
Abstract:
Cognitive impairment (CI) is a widespread clinical syndrome frequently encountered by specialists of various profiles in outpatient settings. Diagnosis of CI is a responsible task, the correct solution of which requires a comprehensive study of the anamnesis, the nature of the clinical picture, and the results of laboratory and instrumental examination. Cerebrovascular diseases are a frequent cause of CI. The article discusses the management of patients with vascular CI, in particular, the main aspects of correcting cardiovascular risk factors and choosing optimal drug therapy. Information is provided on the possibility of using Mexidol for the treatment of this contingent of patients. The results of studies devoted to the possibility of using Mexidol in chronic cerebrovascular disorders with CI are analyzed. Key words:chronic cerebral ischemia, chronic cerebrovascular diseases, cerebral small artery disease, cognitive impairment, Mexidol.